Overview of NDA in Q3 2017 by FDA: ‘Blockbuster’ Potential for Nearly Half of 11 New Drugs
Abstract Time has arrived in the fourth quarter of 2017. There is no doubt that time is the most objective judge and the great things will always withstand the tempered time. FDA approved the ...